Insmed's Phase 1 trial of INS1033 in healthy volunteers is recruiting
A single-site U.S. study testing single and multiple ascending oral doses of INS1033 has been recruiting since late August.
This week's update covers one active early-stage trial for Insmed.
- Insmed's Phase 1, randomized, double-blind, placebo-controlled study of INS1033 in healthy participants is recruiting, with an actual start date of August 25, 2026.1 The trial is testing single and multiple ascending oral doses of INS1033 against placebo, with an estimated enrollment of 116 participants.1 Recruitment is taking place at one site in Salt Lake City, Utah.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.